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ABSTRACT 
Inflammatory cells and inflammatory mediators are crucially involved in the genesis, persistence and severity of 
pain following trauma, infection or nerve injury. The mechanisms and pathways mediating pain and nociception 
are transcriptionally regulated. The transcriptional mediator nuclear factor (NF)-κB plays a major role in 
regulating the inflammatory milieu, ostensibly via the control of gene expression/suppression. An association 
has recently emerged to establish a possible link between NF-κB and pain/nociception, purportedly through the 
regulation of the inflammatory loop and the secretion (biosynthesis) of pro-inflammatory mediators. Current 
concepts conspicuously indicate that the effective inhibition of this transcription factor and associated upstream 
kinase(s) and the pathways that regulate its nuclear translocation could be major targets in a new strategy for the 
alleviation of inflammation and inflammatory-related pain. To better understand this relationship between NF-
κB and the evolution of pain and hyperalgesia/nociception, it is imperative to unravel the molecular basis of this 
process. This survey definitively integrates current themes pertaining to the pivotal role that NF-κB shares in 
regulating pain through the decoding of implicated molecular pathways and signaling mechanisms.  
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1. Introduction and Background 
 
Pain is the most common symptom of injuries and 
diseases (Finnerup and Jensen, 2006; Haddad, 2007). 
Nerve cell endings or receptors, commonly known as 
nociceptors, are central to pain sensation. Nociceptors 
relay information to the CNS thus indicating the 
location, nature and intensity of the ensuing pain. 
 
A nociceptive stimulus unleashes a cascade of events 
throughout the nervous system, which can ultimately 
lead (loop) back to the site of injury (Garry et al., 
2004). This response prompts cells of a variety of 
types in the injured area to release chemicals that 
trigger an immune response and influence the 
intensity and duration of pain (Basbaum and Jessel, 
2000; Saadé et al., 2000; Block et al., 2004). 
 
The inflammatory milieu that usually precedes, and 
accompanies, pain is transcriptionally regulated (Sung 
and Ambron, 2004). Nuclear factor (NF)-κB is a 
transcription factor (TF) essentially involved with 
mediating the release of inflammatory mediators 
(Chen et al., 2002; Haddad, 2002a; Aggarwal, 2004; 
Gilroy et al., 2004; Isomura and Morita, 2006; Nam, 
2006; Park and Christman, 2006), which may 
exacerbate pain, hyperalgesia and nociception 
(Tegeder et al., 2004; Rittner and Brack, 2006; Zhang 
and Huang, 2006).  
 
Current strategies aiming at controlling the origin, and 
propagation, of pain, as well as its manifestations, 
reveal the crucial role that this TF has in modulating 
pain, following the ensuing inflammatory cascade 
(Park and Christman, 2006). Apart from establishing a 
burgeoning trend that stresses the involvement of NF-
κB, however, the mechanisms implicated are still 
being elucidated (Fraser, 2006).  
 
It is the purpose of this survey to amalgamate and 
integrate current concepts in the understanding of how 
this TF regulates pain/nociception, and to correlate 
NF-κB activity with the molecular control of pain. 
 
2. NF-κB: Overview of an inflammatory TF and its 
integration into regulatory pathways 
 
2.1. The nature of the Rel/NF-κB family of TFs 
NF-κB or Rel proteins comprise a family of 
structurally-related eukaryotic TFs (Campbell and 
Perkins, 2006; Xiao et al., 2006). NF-κB mediates the 
expression of an array of genes that are critical for the 
regulation of apoptosis (Haddad and Land, 2000a; 
Anest et al., 2003; Hiscott et al., 2003; Lu et al., 2004; 
Takada et al., 2004; Haddad, 2004b; Piva et al., 2006), 
viral replication (Taddeo et al., 2003), tumorigenensis 
and cancer (Karin and Greten, 2005; Shishodia and 
Aggarwal, 2004; Karin, 2006; Pikarsky and Ben-
Neriah, 2006), inflammation (Haddad and Land, 
2001a; Haddad et al., 2001; Aggarwal, 2004; Gilroy et 
al., 2004), hematopoiesis (Bottero et al., 2006) and 
various autoimmune diseases (Iwahashi et al., 2004; 
Peng, 2004).  
 
Rel/NF-κB proteins are related through a highly 
conserved DNA-binding/dimerization domain called 
the Rel homology (RH) domain (Xiao et al., 2006). 
The Rel/NF-κB proteins are divided into two major 
classes based on sequences C-terminal to the RH 
domain. Members of one class (p105, p100 and 
Drosophila melanogaster Relish) have long C-
terminal domains that contain multiple copies of 
ankyrin repeats, which act to inhibit these molecules 
(Campbell and Perkins, 2006).  
 
Members of this class become active, shorter DNA-
binding proteins [p105 → p50 (NF-κB1); p100 → p52 
(NF-κB2)] by limited proteolysis and/or arrested 
translation. As such, they are generally not activators 
of transcription, except when they form dimers with 
members of the second class of Rel/NF-κB TFs 
(Campbell and Perkins, 2006).  
 
The second class includes c-Rel (p75) (and its 
retroviral homologue v-Rel), RelB (p68), RelA (p65) 
and the Drosophila Dorsal and Dif proteins. This class 
of Rel proteins contains C-terminal transcription 
activation domains, which are often not conserved at 
the sequence level across species, even though they 
can activate transcription in a variety of species 
(Campbell and Perkins, 2006). 
 
Rel/NF-κB TFs bind to 9-10 base pair DNA sites, 
referred to as κB sites, as dimers. All vertebrate Rel 
proteins can form homodimers or heterodimers, 
except for RelB, which can only form heterodimers. 
This combinatorial diversity contributes to the 
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regulation of distinct, but overlapping, sets of genes, 
in that the individual dimers have distinct DNA-
binding site specificities (Vermeulin et al., 2006). The 
term ‘NF-κB’ specifically refers to a p50-p65 
heterodimer, one of the most avidly forming dimers in 
most cells (Fig. 1A).  
 
A B
 
Figure 1: (A) A schematic illustration depicting the NF-κB signaling pathways in response to LPS, TNF and 
related antigens. (B) Various incoming signals converge on the activation of the IκB kinase (IKK) complex by 
reactive oxygen species (ROS) and NF-κB-inducible kinase (NIK). IKK then phosphorylates IκB at 2 N-terminal 
serines, which signals it for ubiquitination and proteolysis (proteasome). Freed NF-κB complex (p50/p65) 
enters the nucleus and activates gene expression. Inhibitors including glucocorticoids suppress the 
transcriptional activity of NF-κB (see Haddad, 2002a). 
 
2.2. The zones and mechanisms of action of NF-κB 
The activation of NF-κB is part of a stress response 
axis as it is activated by a variety of stimuli that 
include growth factors, cytokines, lymphokines, 
ultraviolet (UV), pharmacological agents and 
oxidants/reductants (DiDonato et al., 1997; Haddad et 
al., 2000; Haddad, 2002a; Haddad, 2004b; Chen and 
Greene, 2004; Karin et al., 2004) (Fig. 1B).  
 
The activity of NF-κB is primarily regulated by 
interaction with inhibitory, IκB, proteins (Yamamoto 
and Gaynor, 2004). As with the Rel/NF-κB proteins, 
there are several IκB proteins that have discordant 
affinities for Rel/NF-κB complexes, are regulated 
differently and are expressed in a tissue-specific 
manner (Campbell and Perkins, 2006).  
 
The best-studied NF-κB-IκB interaction is that of 
IκBα with the NF-κB p50-p65 dimer. This interaction 
blocks the ability of NF-κB to bind to DNA and, 
subsequently, results in the NF-κB complex being 
primarily retained in the cytoplasm due to a strong 
nuclear export signal in IκBα (Karin, 2006). That is, 
the NF-κB-IκBα complex is continuously shuttling 
between the nucleus and the cytoplasm, but its rate of 
nuclear export exceeds its rate of import and thus the 
complex is generally cytoplasmic. 
 
From biochemical studies and direct structural 
determinations, it is clear that IκBα makes multiple 
contacts with NF-κB (Karin, 2006). These interactions 
cover sequences of NF-κB that are important for DNA 
binding. In contrast, when IκBβ interacts with the NF-
κB complex, the complex is retained in the cytoplasm 
(i.e., does not necessarily undergo nucleo-cytoplasmic 
shuttling).  
 
NF-κB, thus, is present as a latent, inactive, IκB-
bound cytosolic complex. When a cell receives any of 
a multitude of extracellular signals, NF-κB rapidly 
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enters the nucleus and activates gene expression. 
Therefore, a key step for controlling NF-κB activity is 
the regulation of the IκB-NF-κB interaction. Almost 
all signals that lead to the activation of NF-κB 
converge on the regulation of a high molecular weight 
complex that contains a serine-specific IκB kinase 
(IKK) (Karin, 2006).  
 
In the classical or canonical pathway, activation of 
IKK complex leads to the phosphorylation by IKKβ 
of two specific serines near the N terminus of IκBα, 
which targets IκBα for ubiquitination (generally by a 
complex called β-TrCP) and degradation by the 26S 
proteasome complex. 
 
In the non-canonical pathway, the p100-RelB 
complex is activated by phosphorylation of the C-
terminal region of p100 by an IKKα homodimer 
(lacking IKKγ), which leads to ubiquitination 
followed by degradation of the p100 IκB-like C-
terminal sequences to generate p52-RelB (Karin, 
2006). 
 
 
In either pathway, the unmasked NF-κB complex can 
then enter the nucleus to activate target gene 
expression. In the canonical pathway, intriguingly, 
one of the target genes activated by NF-κB is that 
which encodes IκBα. Newly-synthesized IκBα can 
enter the nucleus, dissociate NF-κB from DNA and 
export the complex back to the cytoplasm to restore 
the original latency (Haddad et al., 2000). Thus, the 
activation of the NF-κB pathway is generally a 
transient process, roughly lasting from 30-60 minutes 
in most cells (Campbell and Perkins, 2006).  
 
The various stimuli that activate NF-κB, therefore, 
cause the phosphorylation of IκB by upstream 
kinases, which is followed by its ubiquitination and 
subsequent degradation (Haddad et al., 2000; Haddad 
et al., 2002; Karin and Greten, 2005) (Fig. 2). This 
results in the exposure of the nuclear localization 
signals (NLS) on NF-κB1 subunit (p50) and the 
subsequent translocation of the molecule (p50-p65 
dimer) to the nucleus. NF-κB generally binds with a 
consensus sequence (5'-GGGACTTTCC-3') of 
various genes and thus activates their transcription 
(Karin et al., 2004; Karin, 2006).  
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Figure 2: NF-κB and the regulation of specialized signaling pathways (see Haddad et al., 2002). 
 
A more thorough discussion on NF-κB signaling 
pathways is beyond the scope of this survey (Fig. 3). 
For that particular reason, we have incorporated up-to-
date references particularly selected for their specific 
themes on NF-κB (Brennan and O’Neill, 1996; Zandi 
et al., 1998; Haddad et al., 2000; Haddad, 2002a; 
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Anest et al., 2003; Aggarwal, 2004; Krakauer, 2004; 
Wajant, 2004; Yamamoto and Gaynor, 2004; Karin et 
al., 2004; Campbell and Perkins, 2006; Karin, 2006).  
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Figure 3: Antioxidant/prooxidant mechanisms in the regulation of inflammatory cytokines. Oxidative stress, 
mainly caused by the depletion of GSH by BSO or conversion onto GSSG, can cause the accumulation of 
ROS. ROS activates downstream effector mechanisms involving upstream kinases, such as MEKK/NIK, which 
regulates the phosphorylation of MKK and IκB/NF-κB complex. Both pathways have the potential to regulate 
genes implicated with cytokine biosynthesis (see Haddad et al., 2000). 
 
 
The following section investigates major concepts of 
pain, nociception and hyperalgesia. 
 
3. Pain and nociception – current concepts 
 
Nociceptive signaling can be considered as a correlate 
of motor reaction (reflex mainly) aiming at protecting 
the living tissue. Nerve endings of thinly myelinated 
and/or unmyelinated fibers are activated by excessive 
stimulation (e.g., mechanical, chemical and thermal) 
that can lead ultimately to a damage or injury (Fig. 4) 
(Kanaan et al., 1996; Wall, 1998; Millan et al., 1999; 
Basbaum and Jessell, 2000; Baliki et al., 2003; 
Almeida et al., 2004; Woolf, 2004a, 2004b).  
 
The beneficial aspect of this signaling and its crucial 
role for survival are strongly suggested from the major 
deformities and limited life-span of individuals with 
congenital analgesia (absence of pain) despite all 
measures made to compensate for this absence (Loro 
et al, 1978; Dyck et al., 1983). From this aspect, acute 
nociception can be considered as a sensory modality 
like touch and taste, with the added survival value just 
alluded to (Cervero and Laird, 1991; Julius and 
Basbaum, 2001). 
 
On the other hand, when nociceptive signaling persists 
for a long period of time exceeding its determining 
causes, it becomes a pathological entity by itself to be 
potentially labeled as chronic pain (Cervero and Laird, 
1991; Saadé et al., 1993a, 1993b; Millan et al., 1999; 
Julius and Basbaum, 2001). The development of this 
entity can be considered as an end-result of a 
persistent cross-talk between environmental and 
neurogenic factors leading, ultimately, to a vicious 
cycle.  
 
This condition usually occurs following tissue injury, 
inflammation and ischemic damage, which can result 
in transient or chronic changes in the environment of 
the nociceptors and in the function of the sensory 
nerve fibers (Wall, 1995; Zimmermann and Herdegen, 
1996; Wall, 1998; Millan et al., 1999). 
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Figure 4: Pain fibers terminate mainly in the superficial dorsal horn (laminae I- II). Aδ fibers enter lamina I (and 
V) and synapse on a second set of neurons. These neurons will carry the signal to the thalamus and are part 
of the spinothalamic tract (STT). The C fibers enter the spinal cord and synapse on lamina I cells and lamina II 
interneurons - neurons that make synaptic connections with other cells within the local environment. The 
interneurons convey the signal to the STT cells that reside mainly in laminae I, IV and V. The axons of the STT 
cells project across the spinal cord to the STT, which is located in the ventrolateral quadrant of the 
contralateral spinal cord white matter (Adapted, courtesy of AnesthesiaUK). 
 
In the case of inflammation or tissue damage, various 
inflammatory mediators and products of tissue 
breakdown are released within a time period ranging 
from minutes to hours. These include bradykinin, 
proteases, histamine, serotonine (5-
hydroxytryptamine, 5-HT), nitric oxide (NO), 
prostanoids, neurotrophins, cytokines, ATP, protons 
and other mediators that are released by injured and/or 
affected (including immune) cells (Dray, 1995; Hunt, 
2000; Hill, 2001; Hunt and Mantyh, 2001; Julius and 
Basbaum, 2001).  
 
Most of these inflammatory products can irritate or 
sensitize the nerve terminals in the affected area, 
which can lead to two main consequences: 
nociceptive signaling and neurogenic inflammation 
(Poole et al., 2000; Saadé et al., 2000; Hunt and 
Mantyh, 2001). The latter can contribute to the direct 
release of neuropeptides (SP, CGRP) (Saadé et al., 
2002; Massaad et al., 2004), or indirect (reflex) 
release of catecholamines through the sympathetic 
efferents (Basbaum and Levine, 1991). Both 
neuropeptides and catocholamines are well known for 
their vasoactive properties and their effects on various 
immune cells (Levine et al., 1986; Payan et al., 1987; 
Safieh-Garabedian et al., 2002) (Fig. 5).  
 
The end result of the cross-talk between immunogenic 
and neurogenic inflammation (Zimmermann and 
Herdegen, 1996; Saadé, et al., 2002; Costa et al., 
2006) is chronic pain, on one side, and the various 
breakdown products in the inflammatory ‘soup’ or 
milieu, on the other hand (Dray, 1994; Poole et al., 
2000), thus leading to the perpetuation of 
inflammation and to induction of critical changes in 
the properties of nerve terminals.  
 
Several important changes in the properties of afferent 
and efferent neurons are observed during chronic pain 
and inflammation (Almeida et al., 2004). These 
include, as illustration: i) activation of silent or 
dormant nociceptors (McMahon and Koltzenburg, 
1990); ii) peripheral and central sensitization, leading 
to hyperalgesia (increased reactivity to nociceptive 
stimuli) and allodynia (nociceptive signaling and/or 
reaction induced by innocuous stimuli under normal 
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conditions) (McMahon and Wall, 1984; Cervero and 
Laird, 1991; Gracely et al., 1992; Coderre et al., 
1993); iii) changes in the ionic channels (Na+ 
channels) (Dib-Hajj et al., 1999) and in the properties 
of membrane receptors (Zimmermann and Herdegen, 
1996; Millan et al., 1999); and iv) significant 
alterations of the electrical signaling behavior of the 
injured and the intact neighboring fibers (Devor and 
Wall, 1990; Devor and Seltzer, 1999).  
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Figure 5: A diagrammatic scheme exhibiting pain pathways, processing and sensitization due to tissue 
damage and inflammatory mediators. 
 
This constellation of events can occur totally, or in 
part, in various clinical and experimental situations 
leading to chronic pain, thus losing its survival value 
as an alarm signal (Basbaum and Levine, 1991; Wall, 
1998) (see Fig. 4).  
 
An important focus of pain research has been the 
study of chronic pain mechanisms, particularly the 
processes that lead to the abnormal sensitivity – 
spontaneous pain and hyperalgesia – that is associated 
with these states. For some time it has been 
recognized that inflammatory mediators released from 
immune cells can contribute to these persistent pain 
states. However, it has only recently become clear that 
immune cell products might have a crucial role not 
just in inflammatory pain, but also in neuropathic pain 
caused by damage to peripheral nerves or to the CNS 
(Marchand et al., 2005).  
 
Because of the presence of a myriad of models alleged 
with pain and pain mechanisms, it is imperative, 
therefore, to dislodge (dissociate) the concepts applied 
with experimental models of pain from those 
associated with pain in humans, likely to be perceived, 
psychologically, physiologically and mechanistically, 
at differential levels. 
 
Recent reports include the inflammatory mediators in 
the special category of neuropathic pains, that are 
initially classified as resulting from discrete or 
obvious damage to the central or peripheral nervous 
systems. These reports are based on animal 
experimentations showing an attenuation of 
neuropathic manifestations by treatment with anti-
inflammatory drugs and especially specific 
antagonists to pro-inflammatory cytokines (Bennett, 
1999; Chacur et al., 2001).  
 
This implies that pro-inflammatory mediators 
(including cytokines) can constitute an end product of 
neurogenic inflammation and can contribute further to 
the neuropathic pain by increasing the inflammatory 
component of the vicious cycle (Deleo et al., 1996; 
Sommer, 2001; Saadé et al., 2002; Sommer, 2003).   
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In conclusion, various strategies have been adopted to 
stop the ‘snow ball’ phenomenon at the origin of 
chronic pain (Saadé et al., 1985; Wall, 1985; Saadé et 
al., 1990; Kanaan et al., 1997; Wall, 1998; Jabbur and 
Saadé, 1999; Hunt, 2000; Garry et al., 2004). These 
include targeting of various mediators, considered to 
play a key role in the inflammatory cascade, and 
based on the use of specific antagonists to 
prostanoids, histamine, neurotrophins and cytokines 
(Saadé et al., 1997; Safieh-Garabedian et al., 1997; 
Saadé et al., 1998; Massaad et al., 2004; Safieh-
Garabedian et al., 2004).  
 
A new strategy has recently emerged and is based on 
targeting the transcription factors at the origin of 
expression of several pro-inflammatory mediators and 
cytokines. The transcription factor of immense 
interest is, undoubtedly, NF-κB.  
 
The following sections will focus on the outcome of 
contemporary research as to understand the NF-κB-
pain nexus and the alleviation of chronic pain through 
specific targeting of this TF potentiating mechanisms.  
 
 
4. NF-κB and the regulation of pain – molecular 
aspects: Is NF-κB a lynchpin? 
 
Nociception and the molecular regulation of pain 
involve key transcription factors, particularly NF-κB 
and related cofactors. The intricate relationship 
between NF-κB and pain is, consequently, rapidly 
evolving. However, the precise mechanisms by which 
NF-κB regulates pain-related pathways are yet to be 
unraveled. Accumulating mounting evidence thereby 
indicates an integral role for this transcription factor in 
the regulation of pain signaling pathways (Lee et al., 
2004; Tegeder et al., 2004; Liuzzo et al., 2007) (Fig. 
6). 
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Figure 6: NF-κB and the regulation of putative pain signaling pathways. 
 
With this in mind, in the upcoming sections there will 
be specific elaboration on the molecular mechanisms 
and pathways associated with NF-κB-mediated 
regulation of pain. 
 
4.1. The repercussions of NF-κB activation at 
localized and centralized nervous sites  
Members of the Rel/NF-κB family of eukaryotic 
transcription factors are activated within the CNS in 
pathological settings of apoptosis and neurological 
diseases (Meffert and Baltimore, 2005). The effect of 
NF-κB activation on pain signaling pathways varies, 
however, with the site (locality) of activation.  
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Certain drugs and/or pain killers can act centrally to 
inhibit NF-κB activation in peripheral acute 
inflammation via a descending neural pathway 
(Ichiyama et al., 1999). Conversely, it was shown that 
IL-1β-induced NF-κB activation may play a role in 
the transmission of immune signals from the 
periphery to the brain (Nadjar et al., 2005). This 
bidirectional influence of NF-κB is central to 
deciphering the molecular codes associated with pain 
and nociception at different levels of hierarchy of 
nervous sites. 
 
To cite another example of the role of NF-κB in the 
aforementioned bidirectional regulatory mechanisms, 
it is worth mentioning that this transcription factor is 
at the center of responses of the peripheral nervous 
system (PNS) to inflammatory cytokines. For 
instance, NF-κB activity was purportedly increased in 
rat dorsal root ganglia (DRG) neurons by tumor 
necrosis factor (TNF), nerve growth factor (NGF) 
(Wood, 1995) and partial sciatic nerve injury (Ma and 
Bisby, 1998). Since these cytokines and/or injurious 
events are at the heart of pain, it appears that the 
regulatory effect of NF-κB is essentially crucial, at 
least in part, for developing the symptoms associated 
with pain and nociception. 
 
This observation is reinforced by another study 
showing that cytokine-mediated activation of NF-κB 
could be a potential component of the signaling 
pathway responsible for the maintenance of adult 
sensory neuron survival following axon damage 
(Fernyhough et al., 2005). In addition, peripheral 
inflammatory pain in sensory ganglia has been shown 
to have been modulated by a specific NF-κB decoy 
(Igwe, 2005). The discussion on the effect of decoys 
on NF-κB-mediated pain will ensue in a subsequent 
section. 
 
Having now investigated the effect of NF-κB on 
central and peripheral inflammatory sites associated 
with pain, it remains of particular interest to indicate 
that NF-κB also seems to be able to modulate 
inflammation and associated pain mechanisms at the 
level of the spinal cord. For example, the spinal 
activation of NF-κB induced cyclooxygenase (COX)-
2 upregulation and contributed to inflammatory pain 
hypersensitivity (Lee at al., 2004). Conversely, 
inhibition of NF-κB activation by the 
antioxidant/prooxidant chemical pyrrolidine 
dithiocarbamate (PDTC) (Haddad et al., 2000) 
attenuated inflammation and oxidative stress after 
experimental spinal cord trauma (La Rosa et al., 
2004).  
 
This is corroborated with the observation that 
manganese-dependent superoxide dismutase (MnSOD 
– the antioxidant enzyme that leads to the dismutation 
of the superoxide radical) as induced by TNF-β is 
regulated transcriptionally by NF-κB following spinal 
cord injury (Yune et al., 2004). Similarly, inhibition of 
astroglial NF-κB reduced inflammation and improved 
functional recovery after spinal cord injury (Brambilla 
et al., 2005). Furthermore, it was reported that there is 
involvement of spinal cord NF-κB activation in 
models of cytokine-induced pain (Ledeboer et al., 
2005). In short, it seems likely to indicate that the 
activation of NF-κB at the level of the spinal cord 
facilitates inflammatory-mediated pain and 
nociception. 
 
Recent work also provided evidence that NF-κB may 
participate in the regulation of neuronal activity-
dependent transcription and behavior under 
pathophysiologic conditions. At the level of the CNS 
in vitro, for example, it was noted that the inhibition 
of IKK decreased LPS-induced COX-2 gene 
expression a glioma cell line (Nakatani et al., 2004), 
implicating a mechanism for anti-inflammatory pain 
therapy. The anti-inflammatory theory on the 
alleviation of pain is subsequently further promoted 
below. 
 
Based on the aforementioned, we can conclude the 
following: i) the localized activation of NF-κB is 
central to the development of inflammatory pain; ii) 
the central activation of this transcription factor 
modulates peripheral pain; and iii) the bidirectional 
effect of NF-κB spanning the range of the spinal cord 
is also essential for the development of inflammatory 
pain (see Fig. 6).   
 
4.2. The effect of NF-κB on inflammatory mediators 
and inflammatory pain  
It has been perceived so far that inflammatory 
mediators are at the center of the effect of NF-κB on 
the evolution of inflammatory pain and nociception. 
In this section I tackle the effect of select 
inflammatory mediators and their role in the 
development of pain. 
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4.2.1. NF-κB and cyclooxygenase regulation  
The association between NF-κB and inflammatory 
pain essentially emerged with the role of COX and 
arachidonic acid (AA) (Mitchell et al., 1997). To cite 
an example, I refer to acetylsalicylic acid (aspirin), 
which is well known to inhibit COX and the release of 
AA; aspirin is purportedly the drug that is most 
commonly self-administered to reduce inflammation, 
swelling (edema) and pain (Yin et al., 1998; Vane and 
Botting, 2003).  
 
Now I should come to a thought on the role of 
cytokines in the regulation of COX, as perceived from 
the tripod nexus of NF-κB, inflammation and pain. 
The identification of a cytokine-inducible isoform of 
COX, known as COX-2 (Mitchell et al., 1997), has 
led to the suggestion that salicylic acid can produce its 
anti-inflammatory actions by downregulating COX-2; 
of particular interest the conception that this inhibitory 
effect is mediated via the downregulation of NF-κB 
(Wu, 2003; Broom et al., 2004). This reinforces the 
suggestion that NF-κB-mediated inflammatory pain is 
COX-dependent. 
 
On a related front, we report a key role of 
prostaglandins (PGs) in the development of pain and 
inflammatory hyperalgesia, an effect that has been 
well documented (Ferreira, 1986; Dray, 1994; Dray, 
1995; Safieh-Garabedian et al., 1997; Ma and 
Eisenach, 2003). For instance, it has been noted that 
interleukin (IL)-1β-mediated induction of COX-2 and 
PGE2 synthesis is dependent on the involvement of a 
mitogen-activated protein kinase (MAPK)p38 and NF-
κB (Fiebich et al., 2000).  
 
Furthermore, the inhibition of NF-κB is reported 
crucial in the treatment of inflammatory pain 
associated with the expression of RANTES (regulated 
on activation, normal T cell expressed and secreted), 
one of the most potent chemokines in allergic and 
infectious disease associated with the expression of 
COX (Zhao et al., 2002) and in clinical models of 
nociception and pain (Valen et al., 2000; Johnson-Pais 
et al., 2003).  
 
Clinically speaking, Rofecoxib, a selective COX-2 
inhibitor approved for the treatment of rheumatoid 
arthritis (RA), inflammatory pain and osteoarthritis, 
has been shown to have proven efficacy in alleviating 
pain and inflammation, ostensibly via the 
downregulation of NF-κB and, to a lesser extent, 
activating protein (AP)-1, another transcription factor 
(Niederberger et al., 2003; Krakauer, 2004; 
Niederberger et al., 2004; Koppert et al., 2004).   
 
COX-2, the major inducer of the release of PGE2 
(Vane and Botting, 2003), has also been reported to 
augment the processing of nociceptive stimuli 
following peripheral inflammation (Ferriera, 1986; 
Lai et al., 2001). The activation of NF-κB is 
associated with the induction of COX-2, thereby 
contributing to the evolution of inflammatory 
hyperalgesia (Balakin et al., 1994; Lee et al., 2004).  
 
Recently, Brummelkamp and coworkers (2003) have 
identified a mechanism implicating acetylsalicylic 
acid in the regulation of NF-κB-mediated apoptosis in 
patients suffering the condition of cylindromatosis 
(familial cylindromatosis is a rare genetic disorder, 
giving rise to neoplasms of the skin appendages.) The 
familial cylindromatosis tumor suppressor gene 
(CYLD) is purported to enhance the activation of NF-
κB by specific binding with IKKγ. The authors 
indicate that inhibition of CYLD increases resistance 
to apoptosis, suggesting a mechanism through which 
loss of CYLD contributes to oncogenesis. This is 
because the loss of the CYLD gene leads to activation 
of NF-κB, a transcription factor having antiapoptotic 
activity. Furthermore, this effect can be relieved by 
aspirin derivatives that inhibit NF-κB activity, 
suggesting a therapeutic intervention strategy to 
restore growth control in patients afflicted with 
familial cylindromatosis (Brummelkamp et al., 2003). 
 
The aforementioned jibes with a clinical trial 
undertaken to treat cylindromatosis patients with 
salicylic acid (Oosterkamp et al., 2006). In cell-based 
assays, salicylate can prevent NF-κB activation 
caused by loss of the cylindromatosis gene, suggesting 
that salicylic acid application might be a potential 
treatment for cylindromatosis. The application of 
salicylate exhibited control over the lesion’s size and 
degree of remission, indicating that the effective 
inhibition of NF-κB may resemble a potential 
therapeutic approach to treating cylindromatosis 
(Oosterkamp et al., 2006). 
 
In summary, NF-κB-mediated upregulation of COX is 
crucial for the release PGs, which in turn exacerbate 
inflammatory pain and hyperalgesia. Acetylsalicylic 
 79
acid may also contribute to the regulation of apoptosis 
associated with inflammation. Conversely, inhibition 
of COX expression by various mediators alleviates 
NF-κB-dependent inflammatory pain. 
 
4.2.2. NF-κB and cytokine regulation 
As has been previously conferred, inflammatory 
molecules regulated by NF-κB exacerbate the 
pathophysiology of pain-related conditions (Sommer 
and Kress, 2004) (see Fig. 5). The secretion of 
inflammatory mediators through NF-κB activation is 
required, for instance, for the induction of allodynia 
(Deleo et al., 1996) and inflammatory pain (Poole et 
al., 2000; Safieh-Garabedian et al., 2002).  
 
To further illustrate this concept, it has been reported 
that IL-10, an anti-inflammatory cytokine, and IL-1ra, 
a soluble IL-1 receptor antagonist, may impede the 
development of dynorphin-induced allodynia via the 
down-regulation of NF-κB and the central pro-
inflammatory cascade (Laughlin et al., 2000). This 
mechanism suggests that NF-κB-dependent 
production of cytokines is required for the induction 
of allodynia. Modulation of NF-κB activity may, 
therefore, prove to be an effective therapeutic strategy 
for the treatment of chronic pain and pain associated 
with inflammation (Safieh-Garabedian et al., 2004).  
 
Nociceptive processing also implicates TNF-α, which 
is regulated by NF-κB (Friedman, 2000; Tegeder et 
al., 2004). Furthermore, cytokines can modulate pain 
in patients with myocardial infarction (MI) and 
unstable nociceptive angina through NF-κB (Ritchie, 
1998; Jenkins, 1999).  
 
In corroboration, this was reinforced with the 
observation that Pseudomonas aeruginosa quorum-
sensing mechanisms were implicated in inducing 
inflammatory pain via the release of cytokines in a 
NF-κB-dependent mechanism (Smith et al., 2002). 
 
IL-1β and TNF-α also induced signs of neuropathic 
pain, associated with the upregulation of p65 (RelA) 
NF-κB subunit in dorsal root ganglia (Zelenka et al., 
2005), thereby indicating a possible central 
mechanism of the algesic effects of cytokines in pain. 
 
Taken together, these observations stress the notion 
that NF-κB-mediated regulation of inflammatory 
cytokines is significant in controlling the processing 
of pain, allodynia, nociception and hyperalgesia 
related mechanisms. 
 
4.3. NF-κB-mediated pain transcriptional 
mechanisms 
The reader’s attention is now diverted to focus on a 
thorough discussion on the molecular mechanisms 
associated with NF-κB-dependent regulation of 
inflammatory pain. 
 
4.3.1. The effect of NF-κB on galanin receptors 
The signaling pathways mediating pain and 
nociception are transcriptionally controlled (Mogil 
and McCarson, 2000; Hunt, 2000; Hill, 2001; Hunt 
and Mantyh, 2001; Julius and Basbaum, 2001). For 
example, the chromosomal location and 
transcriptional regulation of the human galanin-1 
receptor gene (GALN1R), which mediates the effects 
of galanin as a neuroendocrine peptide in modulating 
pain processing and perception, revealed the existence 
of two NF-κB sites (Lorimer et al., 1997). This 
indicates that GALN1R gene expression can be 
regulated as a consequence of inflammatory 
conditions associated with pain in a NF-κB-dependent 
mechanism.    
 
4.3.2. The effect of NF-κB on kinin receptors 
Inflammatory kinins (bradykinin, kallidin) are 
produced at sites of injury and inflammation; they 
serve a critical role in signaling tissue distress as well 
as organizing tissue responsiveness to injury (Dray, 
1997). The acute activation and prolonged 
sensitization of fine afferents, to produce pain and 
hyperalgesia, are important in the protective responses 
that occur to minimize further tissue injury. However, 
the excessive release of inflammatory kinins may, in 
an effect similar to cytokines, exacerbate tissue injury 
and damage. 
 
These inflammatory effects occur through the 
activation of B2 receptors present on sensory neurons, 
resulting in a change of membrane excitability and 
altered cellular neurochemistry. B2 receptor activation 
of a variety of tissues, including postganglionic 
sympathetic fibers, stimulates the production of 
several pro-inflammatory mediators, such as 
prostanoids and cytokines, which further interact with 
kinins and thus contribute to inflammation and 
hyperalgesia (Poole et al., 2000).  
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Similar to the effect of B2 receptors, it has been shown 
that the increased expression of B1 receptors may play 
a prominent role in inflammatory pain and 
hyperalgesia (Ueno and Oh-ishi, 2003; Marceau and 
Regoli, 2004; Calixto et al., 2004). The B1/B2 kinin 
receptors, therefore, play a major role in the mediation 
of inflammatory and pain-related responses (Dray, 
1997).  
 
Molecular and pharmacological evidences show that 
the B1 kinin receptor expression can be regulated 
through endogenous glucocorticoids by NF-κB 
activation (Cabrini et al., 2001). For instance, paw 
edema and contraction of portal vein, mediated by B1 
agonist des-Arg(9)-BK in adrenalectomized (ADX) 
models, were inhibited by dexamethasone or COX-2 
inhibitor, meloxican, and with PDTC, a NF-κB 
inhibitor (Haddad and Land, 2000b; Haddad et al, 
2000).  
 
Interestingly, treatment with dexamethasone, PDTC 
or a combination of both blocked NF-κB activation 
caused by the absence of endogenous glucocorticoid 
(Cabrini et al., 2001). This mechanism supports the 
notion that NF-κB-mediated regulation of kinin 
receptors can modulate inflammation and 
inflammatory pain.  
 
To recapitulate, kinins and kinins’ receptors are potent 
mediators of inflammatory pain, ostensibly via the 
regulation of NF-κB.  
 
4.3.3. The effect of NF-κB on c-fos and NO 
expression 
After having tackled the role of galanin receptors and 
kinins in inflammatory pain, we shift gear to pinpoint 
the effective role of fos-related cofactors in the 
regulation of pain and hyperalgesia. 
 
The involvement of c-fos and neuronal nitric oxide 
synthase (nNOS) in hyperalgesia induced by complete 
Freund’s adjuvant (CFA) has been reported. The 
activation of NF-κB was shown to be pivotal for the 
expression of c-fos (early expression) and nNOS (late 
expression) proteins in response to CFA. Furthermore, 
the behavioral testing of hyperalgesia demonstrated 
that CFA reduced the thresholds for mechanical and 
thermal hyperalgesia, an effect that is NF-κB-
dependent (Chan et al., 2000) (see Fig. 5).  
 
The aforementioned strongly reinforces the ability of 
NF-κB to transcriptionally control the expression of 
cofactors that are essential in the evolution of 
inflammatory pain and hyperalgesia. 
 
4.3.4. The effect of NF-κB decoys on pain 
Pro-inflammatory cytokines and related mediators 
have been reported to be involved in the genesis, 
persistence and severity of neuropathic pain, 
following nerve injury (Costa et al., 2006). The theme 
that emerges quickly is focused on the mechanisms 
that ‘non-classically’ blockade NF-κB. Decoys are at 
the forefront (Inoue et al., 2006; Sun et al., 2006).  
 
In illustration, for example, in a neuropathic pain 
model, NF-κB inhibition using a specific decoy has 
been shown to decrease thermal hyperalgesia via the 
suppression of inflammatory cytokines, inducible 
NOS (iNOS) and adhesion molecules at the site of 
nerve injury (Sakaue et al., 2001).  
 
Another NF-κB decoy was also reported to 
downregulate inflammatory pain associated with 
restenosis in coronary heart disease (Jun-Ichi et al., 
2004). Furthermore, since cytokine imbalance in acute 
coronary syndrome was a major cause of 
inflammatory pain, it was postulated that the 
downregulation of cytokines via transcriptional 
control could be of therapeutic value (Alam et al., 
2004).  
 
In corroboration, another report indicated that the 
modulation of peripheral inflammation by NF-κB 
decoy oligodeoxynucleotide (Igwe, 2005) is 
dependent on the regulation of c-Src kinase, a member 
of the non-receptor tyrosine kinase super family, a 
decreased level of p65 (RelA) NF-κB subunit 
expression and COX-2 inhibition. These observations 
may represent novel pathways for unraveling the 
molecular mechanism of inflammatory pain. 
Therefore, amplifying intrinsic anti-inflammatory 
mechanisms may constitute potential avenues for the 
therapeutic intervention of inflammatory pain. 
 
4.3.5. The effect of NF-κB-related kinases on pain 
I have touched previously on the significant role of 
upstream kinases in the regulation of NF-κB and NF-
κB-mediated regulation of downstream pathways. 
Here, we talk in brevity about the role that upstream 
kinases play in the regulation of inflammatory pain. 
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The specific inhibition of IKK (Rothwarf et al., 2000; 
Haddad et al., 2000; Karin, 2006) was reported to 
downregulate hyperalgesia in neuropathic pain models 
(Tegeder et al., 2004). Furthermore, inhibition of IKK 
activity was shown to prevent injury, infection and 
stress-induced upregulation of pro-inflammatory 
genes, and reduce hyperalgesia and inflammation. The 
involvement of IKK in pain-related mechanisms 
suggests that this kinase may prove to be a novel 
target in the treatment of pathological pain and 
inflammation.  
 
To reinforce this theme, the inhibition of IKK activity 
was similarly shown to downregulate LPS-induced 
COX activation and associated inflammatory pain. 
For example, γ-mangostin, an extract purified from 
the fruit hull of the medicinal plant Garcinia 
mangostana, reduced PGE2 release and COX-2 gene 
expression in vitro (Nakatani et al., 2004). 
Furthermore, an in vitro IKK assay showed that γ-
mangostin inhibited IKK activity in a concentration-
dependent manner.  
 
Consistently, γ-mangostin was also observed to 
decrease LPS-induced IκB degradation and 
phosphorylation. In addition, luciferase reporter 
assays showed that γ-mangostin reduced the LPS-
inducible activation of NF-κB- and human COX-2 
gene promoter region-dependent transcription 
(Nakatani et al., 2004). Taken together, therefore, the 
inhibition of IKK, and subsequently NF-κB target 
genes, may decrease inflammatory pain and, 
essentially, may be a useful mechanism for anti-
inflammatory drug development. 
 
Another family of kinases that is crucial in the 
regulation of NF-κB is MAPKs (see Fig. 2). For 
instance, the activation of the MAPKERK signaling 
cascade by excitotoxic spinal cord injury has been 
shown to implicate NF-κB (Yu and Yezierski, 2005). 
The mechanisms involved a series of transcriptional 
activators, including ELK-1 and CREB. These results 
clearly indicated that injury-induced activation of the 
MAPKERK/NF-κB signaling cascade and the 
transcriptional upregulation of receptors critical in the 
development of chronic pain may be offset by the 
blockade of intracellular kinase cascades involved 
with pain-related behavior. The observation is 
corroborated with the role of MAPKp38 and MAPKJNK 
in NF-κB related induction of pain through C-fibers 
(Liu et al., 2007).  
 
4.4. NF-κB and the regulation of analgesia/anti-
nociception mechanisms 
For now, I have focused on the role of NF-κB in the 
evolution of inflammatory-related pain and 
hyperalgesia. Being a multifaceted TF, it has not 
escaped my attention that this modulator may also be 
involved with antagonistic, analgesic effects. 
 
NF-κB, then, is a major regulator of analgesia and 
related mechanisms of pain regulation too. For 
instance, it has been observed that there was a 
decrease of the electroacupuncture (EA)-induced 
analgesic effects in NF-κB1 (p50) knockout mice 
(p50−/−), suggesting that this TF may play a crucial 
role in both low and high frequency EA-induced 
analgesia (Park et al., 2002). This was in concert with 
the intriguing role of NF-κB in neuronal and immune 
cells mediating inflammation-induced analgesia 
(Borner et al., 2002; Kraus et al., 2003).  
 
What is the likely explanation for this sudden NF-κB 
anti-inflammatory, analgesic effect? In order to 
understand this discrepancy and to reconcile the 
inflammatory and anti-inflammatory effects of this 
TF, we have to decipher yet another code pertaining to 
the key regulatory elements associated with the 
expression of NF-κB. Opioids are, of course, 
legitimate targets. 
 
Analgesic opioids and their receptors are key players 
in a cross-talk between the nervous and immune 
systems (bidirectional neuroimmune interactions) 
(DeLeo et al., 2004; Chen et al., 2007). For example, 
it is established that the endogenous opioid system is 
activated during inflammation as a physiological 
feedback mechanism to attenuate inflammatory pain. 
Nonetheless, what is the exact role of opioids in NF-
κB-dependent analgesia? 
 
Among six putative NF-κB binding sites on the μ-
opioid receptor gene promoter, three cis-active 
elements at nt − 174, − 557, and − 207 were identified 
using transfection experiments of reporter gene 
constructs, EMSA and in vivo binding studies with 
decoy oligonucleotides (Kraus et al., 2003).  
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Allelic variation within the − 557 element was 
reported to reduce its trans-activating potency, which 
may affect regulation of the μ-opioid receptor gene in 
persons carrying this mutation, suggesting a 
regulatory function of inflammatory mediators in 
opioid-mediated processes in neuronal and immune 
cells, with possible impact on the complex of 
inflammation-induced analgesia (Kraus et al., 2003).  
 
Interestingly, excluding the effect of NF-κB with the 
specific inhibitor sulfasalazine, two AP-1 elements, 
which differ in one nucleotide each from the classic 
AP-1 binding site, are delineated to positions − 2388 
and − 1434 of the promoter of the human μ-opioid 
receptor gene (Borner et al., 2002). This suggests that 
a potential cross-talk exists between NF-κB and AP-1 
sites in the regulation of opioid-related sites in 
inflammation. 
 
Molecular events that result in loss of pain perception 
also implicate NF-κB. For example, the receptor for 
advanced glycation end products (RAGE), which is 
associated with sustained NF-κB activation in 
neuropathy, has a central role in sensory neuronal 
dysfunction (Bierhaus et al., 2004).  
 
Interestingly, NF-κB activation was blunted in 
RAGE−/− mice, demonstrating that the RAGE-NF-κB 
axis may operate by mediating functional sensory 
deficits and that its inhibition may provide a 
therapeutic approach in neuropathy (Bierhaus et al., 
2004). Anti-nociception was also reported to be 
associated with the downregulation of NF-κB and 
other inflammatory mediators (Kim et al., 2005), thus 
reinforcing the aforementioned observation. 
 
Furthermore, it was recently shown that spinal 
glucocorticoid receptors through NF-κB may play a 
significant role in the regulation of EAAC1 
(glutamate transporter) expression after peripheral 
nerve injury, a cellular pathway that may contribute to 
the development of neuropathic pain and related 
behaviors in rodents (Wang et al., 2006). This 
suggests that the downregulation of glutamate 
receptor expression and NF-κB are likely mechanisms 
in the effect of glucocorticoids on neuropathic pain 
(Hermoso and Cidlowski, 2003). 
 
In jibe with this concept, it was reported that NF-κB 
activation following peripheral nerve injury could 
contribute to the generation of neuropathic pain. For 
example, it was noted that reciprocal regulation of this 
transcription factor and its inhibitor ZAS3, a zinc 
finger protein, is associated with the development of 
neuropathic-like pain (Wu et al., 2006).  
 
Since ZAS3 is expressed in nervous tissues involved 
in cognitive function and pain modulation, the down-
regulation of ZAS3 after peripheral nerve injury may 
lead to activation of NF-κB, allowing Wallerian 
regeneration and induction of NF-κB-dependent gene 
expression, including pro-inflammatory cytokines. 
This correlates with the observation that 
betamethasone, a corticosteroid, modulates 
neuropathic pain by altering cerebral expression of 
NF-κB and cytokines (Xie et al., 2006). 
 
In contrast with the aforementioned, Frassdorf and 
colleagues (2005) reported that NF-κB was involved 
with morphine-induced myocardial protection and 
pain downregulation. Similar to the effect of LPS, 
morphine induced late preconditioning and activation 
of this transcription factor in the heart in vivo, 
suggesting the involvement of NF-κB in the 
suppression of pain-related pathways implicated with 
acute coronary syndromes (Frassdorf et al., 2005).  
 
This discrepancy in NF-κB dual behavior as far as 
pain and hyperalgesia/analgesia is concerned has to do 
likely with the mechanisms and pathways involved 
with the regulation of this transcription factor. In 
summary, it is observed that the inflammatory milieu, 
which initially is triggered as a protective mechanism, 
may untimely and unexpectedly evolve into a cascade 
of events and injuries exacerbated by the expression 
of NF-κB and related cofactors.  
 
Our assumption of the duality of NF-κB is squared on 
the complexity of the inflammatory cascade and its 
ramifications that may equally dissect into protective 
and/or injurious events, depending on selective 
pathways being activated. This may shed light on why 
pain perception, at least in humans, is so complex yet 
predictable! The mechanisms involved have yet to be 
deciphered. NF-κB and pain pathways are 
schematized in Fig. 6. 
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4.5. NF-κB-independent mechanisms in the 
regulation of pain 
Despite the central role of NF-κB in regulating pain 
and hyperalgesia, as noted, it has been reported that 
there likely exist NF-κB-independent mechanism(s). 
For instance, sodium salicylate was shown to inhibit 
PGE2 release when added together with IL-1β, an 
effect that was independent of NF-κB activation, or 
COX-2 transcription/translation (Mitchell et al., 
1997). Whether other pathways are implicated has yet 
to be determined. In corroboration, it has been 
postulated that sodium salicylate was an effective 
inhibitor of COX-2 activity at concentrations far 
below those required to inhibit NF-κB, a pathway that 
is displaced by AA. 
 
It seems likely that the duality of the nature of NF-κB 
in regulating hyperalgesia and analgesia may pave the 
way for the emerging of other significant cofactors 
that have their share in controlling the mechanisms of 
pain and inflammatory-related pain. I already have 
witnessed a role for MAPKs. My colleagues and I 
(talking as the first author) have previously reported 
NF-κB-independent mechanisms in the regulation of 
inflammatory mediators; MAPKs were attracting 
alternatives (Haddad, 2002b; Haddad, 2004a; Haddad 
and Harb, 2005). 
 
5. Conclusions, summary and prospects 
 
The possible involvement of NF-κB in regulating the 
molecular pathways of nociception has relative 
repercussions on inflammatory-related pain behavior, 
sensation and perception. Evolving research on the 
relationship existing between NF-κB and pain 
(hyperalgesia/analgesia) continues apace, but hitherto 
the race into deciphering the molecular mechanisms is 
even more rapidly developing.  
 
This paper has unraveled several major potential roles 
for NF-κB in the molecular regulation of pain: i) NF-
κB is a major regulator of the gene expression of 
inflammatory mediators, which are at the epicenter of 
the evolution of inflammatory pain; ii) NF-κB-
mediated inflammatory pain and nociception is a 
regulated process, which involves related TFs and/or 
cofactors such as AP-1, c-fos and MAPKs; iii) 
Inflammatory pain is not necessarily an NF-κB-
exclusive event; NF-κB promoted analgesia, 
neuropathic (neurogenic) pain and the expression of 
opioid receptors too; and iv) NF-κB dual nature as a 
promoter of hyperalgesia and, probably, analgesia 
requires thorough understanding of the underlying 
molecular pathways.   
 
Whether the inhibition of this TF, while down-
regulating the protracted inflammatory processes 
likely tarnished with the seal of inflammatory 
mediators, is of real therapeutic value for patients with 
evolving or debilitating pain conditions remains 
fascinating (D’Acquisto et al., 2002; Haddad, 2007). 
Undoubtedly, unraveling the molecular association 
between NF-κB and pain, therefore, would create 
solid grounds for understanding the pain process and 
paves the way for a preventative, alleviating therapy 
for inflammatory-mediated pain.  
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